New Owner for Gallus

A pharmaceutical manufacturing operation at 201 College Road East will have its fifth owner since it was established in 1981.

The factory, which makes an antibody called Prostascint, is owned by St. Louis-based contract manufacturer Gallus, which is being bought out by Durham, North Carolina-based Patheon, and its parent company DPx Holdings. Following the transaction, Patheon will have four facilities in Europe, Australia, and North America, and about 550 employees.

“We are pleased to expand our biologics business with the acquisition of Gallus BioPharmaceuticals,” says Jim Mullen, CEO of DPx Holdings. “This transaction is in line with our strategy. We can now further support the needs of our customers with biologics projects by providing flexibility, leading technology solutions, commercial operations and an expanded footprint with two U.S. sites.”

“This is an exciting time as we join a world-class company and expand our offerings as one global team specializing in biologics,” says Mark R. Bamforth, president and CEO, Gallus BioPharmaceuticals. “We have built deep commercial and clinical manufacturing and process development capabilities that are highly complementary to Patheon’s biologics organization. We look forward to the ongoing success and growth by combining our knowledge, skills, technical expertise, and capabilities to serve customers’ product needs.”

Subject to receipt of regulatory approvals, the transaction is expected to close in the fourth quarter of 2014.

Gallus Biopharmaceuticals NJ LLC, 201 College Road East, Princeton 08540; 609-919-3400; Jeffrey Strand, senior director, site operations. www.gallusbiopharma.com.

CPA Examiner

The American Institute of CPAs has named Michael A. Decker vice president of examinations. In that role, Decker will be responsible for the architecture, development, production, administration, scoring, and maintenance of the CPA examination, a high-stakes test administered in the U.S. and several places overseas.

Decker’s team works in Princeton South Corporate Center in Ewing. Their job is to ensure the exam is valid, reliable, and legally defensible for use in state licensing for CPAs.

Since joining the AICPA in 2008, Decker has led the examinations team through several major changes. He directed the implementation of the 2011 version of the examination that resulted in faster score reporting and the ability to test candidates globally.

Under his direction, the examination team moved into the Princeton South facility, strengthened AICPA’s technological capability, and supported advancements in research and development.

Decker has a bachelor’s in computer science/mathematics from Arcadia University and a master’s in computer science from Villanova University.

American Institute of CPAs (AICPA), 100 Princeton South, Suite 200, Ewing 08628; 609-671-2906; fax, 609-671-2922. Michael Decker, president of examinations. www.aicpa.org.

Collaboration

Advaxis Inc. (ADXS), 305 College Road East, Princeton 08540; 609-452-9813; fax, Daniel J. O’Connor, CEO. www.advaxis.com.

Advaxis, a biotech company based on College Road East, has launched a partnership with pharma giant Merck to test a combination of experimental drugs.

The clinical trial collaboration will test Advaxis’s ADXS-PSA cancer immunotherapy candidate with Merck’s antibody, pembrolizumab. The trial will test the safety and efficacy of the two drugs on patients who have been previously treated for metastatic, castration-resistant prostate cancer. Both drugs are immunotherapies — that is, they are designed to enhance the body’s own defenses against cancer.

“We are excited to be working with Merck. Equally as exciting is the combination potential of our Lm-LLO immunotherapy with Merck’s anti-PD-1 immune checkpoint inhibitor,” said Advaxis CEO Daniel J. O’Connor. “We believe the combination of Advaxis Lm-LLO cancer immunotherapies and checkpoint inhibitors holds significant promise for the treatment of prostate and other cancers.”

Under the terms of the agreement, Advaxis and Merck will collaborate to evaluate the ADXS-PSA/pembrolizumab combination as a treatment for prostate cancer.

Advaxis will sponsor and fund the study and Merck will provide pembrolizumab. The companies will collaboratively oversee the conduct of the study, which is planned to begin in early 2015. Results from the study will be used to determine the path for further clinical development of the combination.

“Collaborations such as this are an integral part of Merck’s strategy to evaluate the potential of pembrolizumab in multiple combinations for a broad range of cancers,” said Eric Rubin, vice president Oncology, Merck Research Laboratories. “We look forward to working with Advaxis to evaluate this novel investigational combination immunotherapy for the treatment of advanced prostate cancer.”

According to the American Cancer Society, prostate cancer is the most common type of cancer found in American men, other than skin cancer. Prostate cancer is the second leading cause of cancer death in men, behind only lung cancer. One man in six will get prostate cancer during his lifetime, and one man in 36 will die of the disease.

Crosstown Moves

Long and Foster Real Estate Inc., 335 Princeton-Hightstown Road, Princeton Junction 08550; 609-275-5101; fax, 609-275-5925. Michael Elliott, office manager. www.longandfoster.com.

The office of Long & Foster Real Estate, formerly located at 33 Princeton-Hightstown Road, has moved to a new location in the Southfield Retail Center at the end of August. The shopping center is home to several restaurants and McCaffrey’s supermarket

“Long & Foster is committed to having the best trained and best equipped agents in the business, and this new office helps us to accomplish those goals — giving us a comfortable working environment that’s designed for both collaboration and education,” said Michael Elliott, branch manager of Long & Foster’s Princeton Junction office. “The expansive cafe-style workspace offers a modern feel with high-tech amenities like a large flat-screen television for client presentations and interactive training sessions. It features state-of-the-art technology and facilities to provide a better training experience and business atmosphere, benefiting both our team and our clients.”

Elliott, who joined the office as its manager in August, will continue to lead the team of about 50 sales associates at the new facility. The team at Long & Foster’s Princeton Junction office offers a number of training programs at its current location, and the new facility will allow the team to host more real estate programs. The office also features executive conference rooms for home buyers and sellers to meet with their agents and discuss their real estate strategies.

Long & Foster plans to hold a grand-opening celebration at the new office, which is located at 335 Princeton-Hightstown Road in West Windsor, in October.

Expansions

Cint USA, 989 Lennox Drive, Suite 208, Lawrenceville 08648; 609-759-0790; fax, Terence McCarron, managing director, North America. www.cint.com.

Cint USA, the North American office of a London-based market research company, has expanded and moved from Route 1 to Lenox Drive in Lawrence.

New in Town

Deallus Consulting Inc., 214 Carnegie Center, Suite 106, Princeton 08540; www.deallusconsulting.com.

Deallus Consulting, a London-based life sciences consulting company specializing in competitive intelligence, has opened an office in Carnegie Center.

The Princeton office will be headed up by Iffat Ali, who joined Deallus as a principal in the New York office, having gained extensive experience working both in industry and pharmaceutical management consulting.

Name Changes

Taylor, Colicchio, and Silverman LLP, 502 Carnegie Center, Suite 103, Princeton 08540; 609-987-0022; fax, 609-987-0070. Paul C. Taylor & Philip M. Colicchio, partners.

Corporate and commercial law firm Taylor, Colichio and Studholme LLP, has removed “Studholme” from the name of the practice and added “Silverman.” Attorney Anne Studholme left to join Rosleand-based Post, Polak, Goodsell, MacNeill, & Strauchler. Stephen B. Silverman joined the firm.

Facebook Comments